Teva Pharmaceutical Industries Stock Forecast
NYSE: TEVAHealthcareDrug Manufacturers - Specialty & GenericUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
TEVA analyst consensus
Consensus (11 analysts)
buy
Avg. price target
$45.30+15.62%
- Strong buy 4
- Buy 6
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 11 Wall Street analysts covering Teva Pharmaceutical Industries (2026-10-08), 10 rate the stock a buy or strong buy, 1 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "buy". The average 12-month price target is $45.30, with a high estimate of $55.00 and a low estimate of $40.00. The average target implies upside of 15.6% from the current price of $39.18.
The spread between the highest and lowest targets is 37.5%, a relatively narrow range. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for TEVA.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 4 | 36% |
| Buy | 6 | 55% |
| Hold | 1 | 9% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-08.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $40.00 | +2.09% |
| Average target | $45.30 | +15.62% |
| High target | $55.00 | +40.38% |